Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses

Journal of Immunology

Volumn 192, Issue 2, 2014, Pages 792-803

  Trist, Halina M ^a   Tan, Peck Szee ^a   Wines, Bruce D ^a,b,c   Ramsland, Paul A ^a,b,c   Orlowski, Eva ^a   Stubbs, Janine ^a   Gardiner, Elizabeth E ^c   Pietersz, Geoffrey A ^a,b,c   Kent, Stephen J ^b   Stratov, Ivan ^b   Burton, Dennis R ^d   Hogarth, P Mark ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR IIA; FC RECEPTOR IIB; HISTIDINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; METHIONINE; PROLINE; TYROSINE;

AMINO ACID SEQUENCE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENETIC POLYMORPHISM; HUMAN; LIGAND BINDING; MACACA FASCICULARIS; MACACA NEMESTRINA; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RHESUS MONKEY; SITE DIRECTED MUTAGENESIS; SPECIES COMPARISON;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; IMMUNOGLOBULIN G; MACACA NEMESTRINA; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; PROTEIN BINDING; RECEPTORS, IGG; SEQUENCE ALIGNMENT;

EID: 84892699191     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301554     Document Type: Article

References (57)

1. Hogarth, P. M., and G. A. Pietersz. 2012. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11: 311-331.
2. Nimmerjahn, F., and J. V. Ravetch. 2010. Antibody-mediated modulation of immune responses. Immunol. Rev. 236: 265-275.
3. Hogarth, P. M. 2002. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 14: 798-802. (Pubitemid 35292429)
4. Cady, C. T., J. S. Rice, V. L. Ott, and J. C. Cambier. 2008. Regulation of hematopoietic cell function by inhibitory immunoglobulin G receptors and their inositol lipid phosphatase effectors. Immunol. Rev. 224: 44-57.
5. Daëron, M., S. Jaeger, L. Du Pasquier, and E. Vivier. 2008. Immunoreceptor tyrosinebased inhibition motifs: a quest in the past and future. Immunol. Rev. 224: 11-43.
6. Daëron, M., and R. Lesourne. 2006. Negative signaling in Fc receptor complexes. Adv. Immunol. 89: 39-86.
7. Tomaras, G. D., G. Ferrari, X. Shen, S. M. Alam, H. X. Liao, J. Pollara, M. Bonsignori, M. A. Moody, Y. Fong, X. Chen, et al. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. USA 110: 9019-9024.
8. Cady, C. T., M. S. Powell, R. J. Harbeck, P. C. Giclas, J. R. Murphy, R. K. Katial, R. W. Weber, P. M. Hogarth, S. Johnson, E. Bonvini, et al. 2010. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgRIIA and FcgRIIB. Immunol. Lett. 130: 57-65.
9. Tate, B. J., E. Witort, I. F. McKenzie, and P. M. Hogarth. 1992. Expression of the high responder/non-responder human FcgRII. Analysis by PCR and transfection into FcR-COS cells. Immunol. Cell Biol. 70: 79-87.
10. Warmerdam, P. A., J. G. van de Winkel, E. J. Gosselin, and P. J. Capel. 1990. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J. Exp. Med. 172: 19-25. (Pubitemid 20217241)
11. Warmerdam, P. A., J. G. van de Winkel, A. Vlug, N. A. Westerdaal, and P. J. Capel. 1991. A single amino acid in the second Ig-like domain of the human Fcg receptor II is critical for human IgG2 binding. J. Immunol. 147: 1338-1343.
12. Ackerman, M. E., A. S. Dugast, E. G. McAndrew, S. Tsoukas, A. F. Licht, D. J. Irvine, and G. Alter. 2013. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b. J. Virol. 87: 5468-5476.
13. Brouwer, K. C., R. B. Lal, L. B. Mirel, C. Yang, A. M. van Eijk, J. Ayisi, J. Otieno, B. L. Nahlen, R. Steketee, A. A. Lal, and Y. P. Shi. 2004. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 18: 1187-1194. (Pubitemid 38738518)
14. Forthal, D. N., G. Landucci, J. Bream, L. P. Jacobson, T. B. Phan, and B. Montoya. 2007. FcγRIIa genotype predicts progression of HIV infection. J. Immunol. 179: 7916-7923.
15. Forthal, D. N., and C. Moog. 2009. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4: 388-393.
16. French, M. A., S. Tanaskovic, M. G. Law, A. Lim, S. Fernandez, L. D. Ward, A. D. Kelleher, and S. Emery. 2010. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a "high-affinity" FcγRIIa genotype. AIDS 24: 1983-1990.
17. Sanders, L. A., J. G. van de Winkel, G. T. Rijkers, M. M. Voorhorst-Ogink, M. de Haas, P. J. Capel, and B. J. Zegers. 1994. Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J. Infect. Dis. 170: 854-861.
18. Solé-Violán, J., M. I. García-Laorden, J. A. Marcos-Ramos, F. R. de Castro, O. Rajas, L. Borderías, M. L. Briones, E. Herrera-Ramos, J. Blanquer, J. Aspa, et al. 2011. The Fcγ receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia. Crit. Care Med. 39: 1388-1393.
19. Duits, A. J., H. Bootsma, R. H. Derksen, P. E. Spronk, L. Kater, C. G. Kallenberg, P. J. Capel, N. A. Westerdaal, G. T. Spierenburg, F. H. Gmelig-Meyling, et al. 1995. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum. 38: 1832-1836. (Pubitemid 26010285)
20. Rascu, A., R. Repp, N. A. Westerdaal, J. R. Kalden, and J. G. van de Winkel. 1997. Clinical relevance of Fcg receptor polymorphisms. Ann. N. Y. Acad. Sci. 815: 282-295. (Pubitemid 27309514)
21. Richards, J. O., S. Karki, G. A. Lazar, H. Chen, W. Dang, and J. R. Desjarlais. 2008. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7: 2517-2527.
22. Chu, S. Y., H. M. Horton, E. Pong, I. W. Leung, H. Chen, D. H. Nguyen, C. Bautista, U. S. Muchhal, M. J. Bernett, G. L. Moore, et al. 2012. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fcengineered antibody. J. Allergy Clin. Immunol. 129: 1102-1115.
23. Weng, W.-K., D. Czerwinski, J. Timmerman, F. J. Hsu, and R. Levy. 2004. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22: 4717-4724.
24. Nguyen, D. C., F. Scinicariello, and R. Attanasio. 2011. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics 63: 351-362.
25. Rogers, K. A., F. Scinicariello, and R. Attanasio. 2004. Identification and characterization of macaque CD89 (immunoglobulin A Fc receptor). Immunology 113: 178-186. (Pubitemid 39312445)
26. Rogers, K. A., F. Scinicariello, and R. Attanasio. 2006. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J. Immunol. 177: 3848-3856. (Pubitemid 44359919)
27. Warncke, M., T. Calzascia, M. Coulot, N. Balke, R. Touil, F. Kolbinger, and C. Heusser. 2012. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J. Immunol. 188: 4405-4411.
28. Chapman, K., N. Pullen, M. Graham, and I. Ragan. 2007. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat. Rev. Drug Discov. 6: 120-126. (Pubitemid 46745340)
29. Chapman, K. L., L. Andrews, J. J. Bajramovic, P. Baldrick, L. E. Black, C. J. Bowman, L. A. Buckley, L. A. Coney, J. Couch, A. Maggie Dempster, et al. 2012. The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates. Regul. Toxicol. Pharmacol. 62: 347-354.
30. SF162P3-infected infant rhesus macaques. J. Virol. 87: 10447-10459.
31. Joag, S. V., Z. Li, C. Wang, L. Foresman, F. Jia, E. B. Stephens, W. Zhuge, and O. Narayan. 1999. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simianhuman immunodeficiency virus failed to protect against mucosally inoculated virus. AIDS Res. Hum. Retroviruses 15: 391-394. (Pubitemid 29115933)
32. Ng, C. T., J. P. Jaworski, P. Jayaraman, W. F. Sutton, P. Delio, L. Kuller, D. Anderson, G. Landucci, B. A. Richardson, D. R. Burton, et al. 2010. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16: 1117-1119.
33. Brenchley, J. M. 2013. Mucosal immunity in human and simian immunodeficiency lentivirus infections. Mucosal Immunol. 6: 657-665.
34. Widjaja, S., I. Winoto, J. Sturgis, C. N. Maroef, E. Listiyaningsih, R. Tan, J. Pamungkas, P. J. Blair, D. Sajuthi, and K. R. Porter. 2010. Macaca nemestrina and dengue virus infectivity: a potential model for evaluating dengue vaccine candidates. Micobiol. Indonesia 4: 49-54.
35. Reece, J. C., S. Alcantara, S. Gooneratne, S. Jegaskanda, T. Amaresena, C. S. Fernandez, K. Laurie, A. Hurt, S. L. O'Connor, M. Harris, et al. 2013. Trivalent live attenuated influenza-simian immunodeficiency virus vaccines: efficacy and evolution of cytotoxic T lymphocyte escape in macaques. J. Virol. 87: 4146-4160.
36. Reece, J. C., L. Loh, S. Alcantara, C. S. Fernandez, J. Stambas, A. Sexton, R. De Rose, J. Petravic, M. P. Davenport, and S. J. Kent. 2010. Timing of immune escape linked to success or failure of vaccination. PLoS ONE 5: e12774.
37. Wines, B. D., H. M. Trist, R. C. Monteiro, C. Van Kooten, and P. M. Hogarth. 2004. Fc receptor γ chain residues at the interface of the cytoplasmic and transmembrane domains affect association with FcαRI, surface expression, and function. J. Biol. Chem. 279: 26339-26345. (Pubitemid 38798784)
38. Stuart, S. G., N. E. Simister, S. B. Clarkson, B. M. Kacinski, M. Shapiro, and I. Mellman. 1989. Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG-transporting placental epithelium. EMBO J. 8: 3657-3666. (Pubitemid 20016044)
39. Powell, M. S., N. C. Barnes, T. M. Bradford, I. F. Musgrave, B. D. Wines, J. C. Cambier, and P. M. Hogarth. 2006. Alteration of the FcγRIIa dimer interface affects receptor signaling but not ligand binding. J. Immunol. 176: 7489-7494. (Pubitemid 43849052)
40. Ramsland, P. A., W. Farrugia, T. M. Bradford, C. T. Sardjono, S. Esparon, H. M. Trist, M. S. Powell, P. S. Tan, A. C. Cendron, B. D. Wines, et al. 2011. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 187: 3208-3217.
41. Hibbs, M. L., L. Bonadonna, B. M. Scott, I. F. McKenzie, and P. M. Hogarth. 1988. Molecular cloning of a human immunoglobulin G Fc receptor. Proc. Natl. Acad. Sci. USA 85: 2240-2244. (Pubitemid 24315866)
42. Ierino, F. L., M. D. Hulett, I. F. McKenzie, and P. M. Hogarth. 1993. Mapping epitopes of human FcγRII (CDw32) with monoclonal antibodies and recombinant receptors. J. Immunol. 150: 1794-1803. (Pubitemid 23129655)
43. Looney, R. J., G. N. Abraham, and C. L. Anderson. 1986. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J. Immunol. 136: 1641-1647. (Pubitemid 16119569)
44. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
45. Choi, E. I., R. Wang, L. Peterson, N. L. Letvin, and K. A. Reimann. 2008. Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques. Immunology 124: 215-222. (Pubitemid 351692902)
46. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234: 779-815. (Pubitemid 24007801)
47. Krissinel, E., and K. Henrick. 2007. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372: 774-797. (Pubitemid 47321791)
48. Bohne-Lang, A., and C.-W. von der Lieth. 2005. GlyProt: in silico glycosylation of proteins. Nucleic Acids Res. 33(Web Server issue): W214-W219. (Pubitemid 44529911)
49. Hulett, M. D., E. Witort, R. I. Brinkworth, I. F. McKenzie, and P. M. Hogarth. 1995. Multiple regions of human FcγRII (CD32) contribute to the binding of IgG. J. Biol. Chem. 270: 21188-21194.
50. Maxwell, K. F., M. S. Powell, M. D. Hulett, P. A. Barton, I. F. McKenzie, T. P. Garrett, and P. M. Hogarth. 1999. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat. Struct. Biol. 6: 437-442. (Pubitemid 29218012)
51. Hulett, M. D., I. F. McKenzie, and P. M. Hogarth. 1993. Chimeric Fc receptors identify immunoglobulin-binding regions in human FcγRII and FcεRI. Eur. J. Immunol. 23: 640-645. (Pubitemid 23095097)
52. Hulett, M. D., E. Witort, R. I. Brinkworth, I. F. McKenzie, and P. M. Hogarth. 1994. Identification of the IgG binding site of the human low affinity receptor for IgG FcγRII. Enhancement and ablation of binding by site-directed mutagenesis. J. Biol. Chem. 269: 15287-15293.
53. Syam, S., P. Mero, T. Pham, C. A. McIntosh, P. Bruhns, and J. W. Booth. 2010. Differential recruitment of activating and inhibitory FcγRII during phagocytosis. J. Immunol. 184: 2966-2973.
54. Jacobsen, F.W., R. Padaki, A. E. Morris, T. L. Aldrich, R. J. Armitage, M. J. Allen, J. C. Lavallee, and T. Arora. 2011. Molecular and functional characterization of cynomolgus monkey IgG subclasses. J. Immunol. 186: 341-349.
55. Stavenhagen, J. B., S. Gorlatov, N. Tuaillon, C. T. Rankin, H. Li, S. Burke, L. Huang, S. Vijh, S. Johnson, E. Bonvini, and S. Koenig. 2007. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 67: 8882-8890. (Pubitemid 47437465)
56. Chu, S. Y., J. R. Desjarlais, S. B. Karki, G. A. Lazar, G. L. Moore, and I. Vostiar. 2011. Methods and compositions for inhibiting CD32B expressing cells. U.S. Patent Application 12/156,183. 2011, Nov 22.
57. Boonnak, K., B. M. Slike, G. C. Donofrio, and M. A. Marovich. 2013. Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J. Immunol. 190: 5659-5665.